new BindingDB logo
myBDB logout

80 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
8230117 4 The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.EBI SmithKline Beecham Pharmaceuticals
1479586 8 New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.EBI Kyowa Hakko Kogyo Co., Ltd.
1656043 4 New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.EBI Universidad de Navarra
2153209 6 Synthesis and cardiotonic activity of novel biimidazoles.EBI Merrell Dow Research Institute
2738882 9 Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.EBI Lilly Research Laboratories
2846840 20 Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).EBI Syntex Research
3039132 26 Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.EBI TBA
3965705 10 2-(beta-Arylethylamino)- and 4-(beta-arylethylamino)quinazolines as phosphodiesterase inhibitors.EBI TBA
14980691 15 Orally active PDE4 inhibitors with therapeutic potential.EBI Minase Research Institute
14684291 14 New orally active PDE4 inhibitors with therapeutic potential.EBI Minase Research Institute
14684329 27 Highly potent PDE4 inhibitors with therapeutic potential.EBI Minase Research Institute
12668000 29 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.EBI National Institute of Pharmaceutical Education and Research (NIPER)
12852946 69 Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors.EBI National Institute of Pharmaceutical Education and Research
12824031 26 Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.EBI Tanabe Seiyaku Co., Ltd.
11814830 26 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.EBI Celltech R& D
12039576 17 Synthesis and profile of SCH351591, a novel PDE4 inhibitor.EBI Schering-Plough Corporation
12039575 18 8-Methoxyquinolines as PDE4 inhibitors.EBI Schering-Plough Corporation
12039574 16 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.EBI Celltech R&D
11738561 34 Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.EBI Zambon Group
11140727 31 Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.EBI Zambon Group
11128646 69 Synthesis and biological evaluation of 2,5-dihydropyrazol.EBI Rhône-Poulenc Rorer
11012037 25 The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.EBI Zambon Group
10999488 34 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.EBI Celltech-Chiroscience Ltd
10636238 71 Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.EBI Institut de Recherche Jouveinal-Parke Davis
9871607 32 Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.EBI Rhône-Poulenc Rorer
9871693 46 Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.EBI Rh£ne-Poulenc Rorer Central Research
9873675 44 Orally active indole N-oxide PDE4 inhibitors.EBI Rh£ne-Poulenc Rorer Central Research
9873649 25 PDE4 inhibitors: new xanthine analogues.EBI Chiroscience Ltd
9871649 26 Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.EBI Rh£ne-Poulenc Rorer Central Research
9873600 14 Thalidomide analogs and PDE4 inhibition.EBI Celgene Corporation
9873613 15 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.EBI Rh£ne-Poulenc Rorer
9873593 15 Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.EBI Chiroscience Ltd
9873449 49 The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.EBI Rh£ne-Poulenc Rorer Central Research
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
26681511 33 Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.EBI Sanofi Research Center
26526739 35 Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.EBI Southern Medical University
26288683 43 Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.EBI Bristol-Myers Squibb R&D
26005524 147 Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.EBI Merck Research Laboratories
25736998 37 Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.EBI Merck Serono Research& Development
22780914 35 Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.EBI Pfizer Inc.
22963052 38 Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.EBI VU University Amsterdam
22891752 18 Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.EBI Universidade Federal do Rio de Janeiro
18686943 28 Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.EBI Matrix Laboratories Limited
17228876 36 SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.EBI Pfizer Global Research and Development
16168647 80 Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.EBI Merck Frosst Centre for Therapeutic Research
15887951 29 The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.EBI Monash University (Parkville Campus)
11405657 123 Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.EBI Tanabe Seiyaku Co., Ltd.
10691693 64 Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.EBI Novartis Pharma AG
10090791 77 Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.EBI Tanabe Seiyaku Company, Ltd.
8388468 37 Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.EBI SmithKline Beecham Pharmaceuticals
12824030 67 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.EBI Tanabe Seiyaku Co., Ltd.
11755362 24 Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.EBI Novartis Pharma AG
21955943 47 Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.EBI Pfizer Inc.
20709547 69 The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.EBI Merck Frosst Centre for Therapeutic Research
20196613 32 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI Pfizer Global Research and Development
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19919087 55 Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.EBI Pfizer Global Research and Development
 5 The Gif system as a tool in medicinal chemistry: The oxidation of Sch 57726 under GoAggIII conditionsEBI TBA
19339180 69 The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI Pfizer Global Research and Development
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
16516471 114 Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.EBI Merck Frosst Center for Therapeutic Research
16275071 26 A new chemical tool for exploring the physiological function of the PDE2 isozyme.EBI Pfizer, Inc.
16263279 37 A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.EBI Pfizer, Inc.
15149695 24 New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.EBI Pfizer Global Research and Development
14521415 44 The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.EBI Centre de Recherches
11958981 25 Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.EBI BAYER AG
10937713 186 Solid-phase synthesis of an arylsulfone hydroxamate library.EBI Rhone Poulenc Rorer
10197972 133 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.EBI Tanabe Seiyaku Company, Ltd.
9873594 44 Aryl sulfonamides as selective PDE4 inhibitors.EBI Chiroscience Ltd
9464356 24 Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.EBI Pfizer Inc.
8496906 127 Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position.EBI Hokuriku University
2544722 94 Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.EBI Centre de Neurochimie du CNRS
1331453 106 Effects of alkyl substitutions of xanthine skeleton on bronchodilation.EBI Hokuriku University
17629487 20 Alpha-substituted N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists.BDB Seoul National University